Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO
publication date: Aug 12, 2019
China's Chipscreen Bio gained a stunning 367% in its first trading session following its IPO on the Shanghai STAR exchange, giving the company a market cap of $4.2 billion, When the first 25 STAR Board IPOs hit the market last month, the average gain was 140%, which was considered a huge jump. Chipscreen was 2.5 times larger. Chipscreen develops small molecule drugs for cancer, diabetes, endocrine and autoimmune diseases. It priced its IPO 27% above its original target and raised $148 million, an amount that now seems charmingly quaint. More details....
Stock Symbol: (SHA: 688321)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.